Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C45H57N3O9 |
Molecular Weight | 783.9488 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)[C@H]1OC(=O)[C@H](CC2=CC=CC=C2)N(C)C(=O)[C@H](OC(=O)[C@H](CC3=CC=CC=C3)N(C)C(=O)[C@H](OC(=O)[C@H](CC4=CC=CC=C4)N(C)C1=O)C(C)C)C(C)C
InChI
InChIKey=GYSCAQFHASJXRS-FFCOJMSVSA-N
InChI=1S/C45H57N3O9/c1-28(2)37-40(49)46(7)35(26-32-21-15-11-16-22-32)44(53)56-39(30(5)6)42(51)48(9)36(27-33-23-17-12-18-24-33)45(54)57-38(29(3)4)41(50)47(8)34(43(52)55-37)25-31-19-13-10-14-20-31/h10-24,28-30,34-39H,25-27H2,1-9H3/t34-,35-,36-,37+,38+,39+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22367030Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23877026
https://www.ncbi.nlm.nih.gov/pubmed/25178661
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22367030
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23877026
https://www.ncbi.nlm.nih.gov/pubmed/25178661
Beauvericin is a famous mycotoxin produced by many fungi, such as Beaveria bassiana and Fusarium spp. Beauvericin is a cyclic hexadepsipeptide (Figure 1) that belongs to the enniatin antibiotic family. It contains three D-hydroxyisovaleryl and three N-methylphenylalanyl residues in an alternating sequence. Beauvericin was first isolated from Beaveria bassiana, which is a common and commercial entomopathogenic mycoinsecticide. Beauvericin was one of the active constituents of B. bassiana and was confirmed to have antimicrobial and anti-tumor activities. Beauvericin has a strong antibacterial activity against human, animal and plant pathogenic bacteria with no selectively between Gram-positive and Gram-negative bacteria. The cytotoxicity of beauvericin to human tumor cells has been frequently reported.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22367030
Curator's Comment: The insecticidal activity of beauvericin was first discovered by Hamill et al.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25178661 |
|||
Target ID: CHEMBL394 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25178661 |
2.4 µM [EC50] | ||
Target ID: CHEMBL395 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25178661 |
3.6 µM [EC50] | ||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23877026 |
3.09 µM [IC50] | ||
Target ID: CHEMBL387 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23877026 |
2.02 µM [IC50] | ||
Target ID: CHEMBL392 |
0.82 µM [IC50] | ||
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21497643 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Antimycobacterial and antiplasmodial cyclodepsipeptides from the insect pathogenic fungus Paecilomyces tenuipes BCC 1614. | 2000 Dec |
|
Block of L-type Ca2+ current by beauvericin, a toxic cyclopeptide, in the NG108-15 neuronal cell line. | 2002 Jun |
|
An investigation of the ionophoric characteristics of destruxin A. | 2002 Sep 1 |
|
Presence and concentrations of the Fusarium-related mycotoxins beauvericin, enniatins and moniliformin in finnish grain samples. | 2004 Aug |
|
Fusaproliferin, beauvericin and fumonisin production by different mating populations among the Gibberella fujikuroi complex isolated from maize. | 2004 Feb |
|
Supercritical fluid extraction of Beauvericin from maize. | 2004 Feb 27 |
|
Phylogenetic analyses of the Fusarium poae, Fusarium sporotrichioides and Fusarium langsethiae species complex based on partial sequences of the translation elongation factor-1 alpha gene. | 2004 Sep 15 |
|
Diversity in metabolite production by Fusarium langsethiae, Fusarium poae, and Fusarium sporotrichioides. | 2004 Sep 15 |
|
Occurrence of mycotoxin in Farro samples from southern Italy. | 2005 Feb |
|
Beauvericin activates Ca2+-activated Cl- currents and induces cell deaths in Xenopus oocytes via influx of extracellular Ca2+. | 2005 May |
|
Effects of beauvericin on the metabolic state and ionic homeostasis of ventricular myocytes of the guinea pig. | 2005 Nov |
|
Search for cell motility and angiogenesis inhibitors with potential anticancer activity: beauvericin and other constituents of two endophytic strains of Fusarium oxysporum. | 2007 Feb |
|
Fusarium avenaceum -- the North European situation. | 2007 Oct 20 |
|
Complex etiology, prophylaxis and hygiene control in mycotoxic nephropathies in farm animals and humans. | 2008 Apr |
|
Statistical optimization of growth medium for the production of the entomopathogenic and phytotoxic cyclic depsipeptide beauvericin from Fusarium oxysporum KFCC 11363P. | 2008 Jan |
|
Diversity in Beauvericin and Enniatins H, I, and MK1688 by Fusarium oxysporum isolated from potato. | 2008 Mar 20 |
|
Biosynthesis of the cyclooligomer depsipeptide beauvericin, a virulence factor of the entomopathogenic fungus Beauveria bassiana. | 2008 Sep 22 |
|
Beauvericin and enniatins H, I and MK1688 are new potent inhibitors of human immunodeficiency virus type-1 integrase. | 2009 Dec |
|
LC-MS/MS multi-analyte method for mycotoxin determination in food supplements. | 2009 Jun |
|
Formation of fumonisins and other secondary metabolites by Fusarium oxysporum and F. proliferatum: a comparative study. | 2010 May |
|
Contamination by moulds of grape berries in Slovakia. | 2010 May |
|
Mycotoxin production of selected Fusarium species at different culture conditions. | 2010 Sep 30 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27349679
0.2 mg/kg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25178661
Incubation of H4IIE cells with beauvericin (10uM, 2 h) strongly diminished phosphorylation of the MAP kinase ERK (p44/p42) as a prerequisite of MAPK activation
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1976
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3000
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
DTXSID00891834
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
26048-05-5
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
3007984
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
C004456
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
26S048LS2R
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
C1011
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY | |||
|
BEAUVERICIN
Created by
admin on Sat Dec 16 02:16:39 GMT 2023 , Edited by admin on Sat Dec 16 02:16:39 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD